# Chinese University of Hong Kong: Not applicable (device, behavioral) study in Bladder Cancer (440 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Sponsor type | Academic and hospital |
| Study | The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC |
| NCT ID | NCT07907575 |
| Phase | Not applicable (device, behavioral) |
| Status | not yet recruiting |
| Conditions | Bladder Cancer |
| Intervention types | drug, procedure |
| Target enrollment | 440 |
| Site countries | Hong Kong |
| Posted | 2026-10-30 |
| Planned start | 2027-01-01 |
| Event | Newly registered study |
| Event date | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- 440 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07907575). Last refreshed: 2026-11-06T09:49:51.899Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.